Javascript must be enabled to continue!
Endoscopic features of deficient mismatch repair/microsatellite instability‐high and BRAF‐mutated colorectal cancer
View through CrossRef
AbstractObjectiveRecent advancements in genome analyses, including the BRAF gene and mismatch repair (MMR) gene/microsatellite instability (MSI), have revealed the biological diversity of colorectal cancer (CRC). BRAF‐mutated CRC has a poor prognosis; however, cases exhibiting deficient MMR (dMMR)/MSI‐high (MSI‐H) and BRAF gene mutations have demonstrated significant prognostic improvement following recent immune checkpoint inhibitor therapy. Therefore, the diagnosis of these subtypes is important. This study aimed to identify the endoscopic features of dMMR/MSI‐high and BRAF‐mutated CRCs.MethodsA retrospective analysis was conducted on 292 CRC cases. Clinicopathological findings, focusing on dMMR/MSI‐H and BRAF‐mutated subtypes, were determined. Endoscopic images were analyzed for the presence of yellow slough. Surface material characteristics were assessed through a histopathological evaluation.ResultsOf the 256 cases analyzed, 27 were dMMR/MSI‐H CRC, including 12 BRAF‐mutant cases. Yellow slough was observed in 83.3% of dMMR/MSI‐H and BRAF‐mutated CRCs, compared with 13.3% dMMR/MSI‐H and BRAF wild‐type CRCs and 1.3% pMMR/MSS and BRAF wild‐type CRCs. Histological examination showed a correlation of yellow slough with coagulative necrosis and thicker surface layers in dMMR/MSI‐high and BRAF‐mutated CRCs.ConclusionYellow slough on endoscopy may help identify dMMR/MSI‐H‐ and BRAF‐mutated CRC and allow the initiation of appropriate molecular testing and immunotherapy
Title: Endoscopic features of deficient mismatch repair/microsatellite instability‐high and BRAF‐mutated colorectal cancer
Description:
AbstractObjectiveRecent advancements in genome analyses, including the BRAF gene and mismatch repair (MMR) gene/microsatellite instability (MSI), have revealed the biological diversity of colorectal cancer (CRC).
BRAF‐mutated CRC has a poor prognosis; however, cases exhibiting deficient MMR (dMMR)/MSI‐high (MSI‐H) and BRAF gene mutations have demonstrated significant prognostic improvement following recent immune checkpoint inhibitor therapy.
Therefore, the diagnosis of these subtypes is important.
This study aimed to identify the endoscopic features of dMMR/MSI‐high and BRAF‐mutated CRCs.
MethodsA retrospective analysis was conducted on 292 CRC cases.
Clinicopathological findings, focusing on dMMR/MSI‐H and BRAF‐mutated subtypes, were determined.
Endoscopic images were analyzed for the presence of yellow slough.
Surface material characteristics were assessed through a histopathological evaluation.
ResultsOf the 256 cases analyzed, 27 were dMMR/MSI‐H CRC, including 12 BRAF‐mutant cases.
Yellow slough was observed in 83.
3% of dMMR/MSI‐H and BRAF‐mutated CRCs, compared with 13.
3% dMMR/MSI‐H and BRAF wild‐type CRCs and 1.
3% pMMR/MSS and BRAF wild‐type CRCs.
Histological examination showed a correlation of yellow slough with coagulative necrosis and thicker surface layers in dMMR/MSI‐high and BRAF‐mutated CRCs.
ConclusionYellow slough on endoscopy may help identify dMMR/MSI‐H‐ and BRAF‐mutated CRC and allow the initiation of appropriate molecular testing and immunotherapy.
Related Results
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
<div>Abstract<p>One of the most encouraging developments in oncology has been the success of BRAF inhibitors in <i>BRAF</i>-mutant melanoma. However, in con...
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
<div>Abstract<p>One of the most encouraging developments in oncology has been the success of BRAF inhibitors in <i>BRAF</i>-mutant melanoma. However, in con...
Abstract 468: BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: results from the prospective study GEM1304 (Spanish Melanoma Group)
Abstract 468: BRAF mutation analysis in cell free tumoral DNA (cfDNA) of melanoma patients: results from the prospective study GEM1304 (Spanish Melanoma Group)
Abstract
Backgroud: Tumor-derived circulating cell-free DNA (cfDNA) is a dynamic source for determination of tumor mutation status. We have previously demonstrated t...
Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.
Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.
70
Background:
BRAFV600E-mutant metastatic colorectal cancer (mCRC) represents a unique molecular subset with poor prognosis and less ...
Somatic BRAF-V600E Mutations in Familial Colorectal Cancer
Somatic BRAF-V600E Mutations in Familial Colorectal Cancer
Abstract
The BRAF gene is mutated in 4% to 12% of unselected colorectal cancers, particularly those with high microsatellite instability and in premalignant lesions,...
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract A13: Applied the proteomics characteristics to detect the inherited colorectal adenomas
Abstract
Introduction: Current study found that about one-third of the incidence of colorectal cancer have genetic related. Hereditary nonpolyposis colorectal cancer...
Impact of Micronutrient Profiles on the Pathological Features and Clinical Outcomes of Colorectal Tumors with Microsatellite Instability
Impact of Micronutrient Profiles on the Pathological Features and Clinical Outcomes of Colorectal Tumors with Microsatellite Instability
We assessed the role of nutritional factors in conjunction with pathological and clinical characteristics of colorectal tumors with microsatellite instability. Data from 1,135 pati...
Abstract 6979: Uncovering the BRAF interactome to identify novel therapeutic targets for BRAF driven melanoma and lung cancer
Abstract 6979: Uncovering the BRAF interactome to identify novel therapeutic targets for BRAF driven melanoma and lung cancer
Abstract
BRAF protein kinases act downstream of RAS-GTP and upstream of MEK>ERK MAP Kinase signaling. Notably, mutational activation of BRAF is a driver of ap...

